Prevention of @entity301 with @entity8673 in XXXX with @entity1007 . West of Scotland Coronary Prevention Study Group.

@entity1 @entity1007 @entity301 @entity583 @entity204 @entity8673 @entity165
BACKGROUND: Lowering the blood @entity165 level may reduce the risk of @entity301 . This double-blind study was designed to determine whether the administration of @entity8673 to @entity1 with @entity1007 and no history of @entity583 reduced the combined incidence of nonfatal @entity583 and @entity204 from @entity301 . METHODS: We randomly assigned 6595 @entity1 , 45 to 64 years of age, with a mean (+/- SD) plasma @entity165 level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive @entity8673 (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national @entity204 registry were used to determine the clinical end points. RESULTS: @entity8673 lowered plasma @entity165 levels by 20 percent and low-density-lipoprotein @entity165 levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal @entity583 or @entity204 from @entity301 ) in the placebo group, and 174 in the @entity8673 group (relative reduction in risk with @entity8673 , 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal @entity583 (31 percent reduction, P < 0.001), @entity204 from @entity301 (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and @entity204 from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the @entity8673 group. We observed a 22 percent reduction in the risk of @entity204 from any cause in the @entity8673 group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with @entity8673 significantly reduced the incidence of @entity583 and @entity204 from cardiovascular causes without adversely affecting the risk of @entity204 from noncardiovascular causes in @entity1 with moderate @entity1007 and no history of @entity583 .
